NCT05226338

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

A Phase 1, Open-Label, Randomized, Single Dose, 3-Period, 3-Treatment Study to Evaluate the Relative Bioavailability of D-0502 Tablet Formulations in Healthy Female Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: InventisBio Co., Ltd · Industry
• Sex: Female
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Relative Bioavailability study of D-0502 tablet formulation in healthy female subjects

Detailed description

Phase 1, Open Label, Randomized, Single dose, 3 Period, 3 treatment study to evaluation the relative Bioavailability of D-0502 tablet formulation in healthy female subjects

Conditions

• Healthy Female Volunteer

Interventions

Type	Name	Description
DRUG	D-0502	Formulation 1 Formulation 2 Formulation 3

Timeline

• Start date: 2021-10-27
• Primary completion: 2021-12-23
• Completion: 2022-05-11
• First posted: 2022-02-07
• Last updated: 2022-08-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study